logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers, Meso Scale To Develop Diagnostic Assays For Alzheimer's Disease

Bristol-Myers Squibb Co. (BMY) and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

As per the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer's disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

Alzheimer's disease is a progressive brain disease that impairs memory, interferes with thinking and ultimately destroys the ability of an individual to carry out simple tasks. The disease is a continuum, with damage to the brain starting long before the onset of dementia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sporting goods retailer Dick's Sporting Goods, Inc. has emerged as the successful bidder in the bankruptcy auction for its former rival Sports Authority Holding Inc.'s intellectual property assets and the right to acquire 31 store leases. Swedish music streaming app Spotify says that Apple has rejected an update of its iOS app. One of the top marketing executives of Chipotle Mexican Grill Inc., Mark Crumpacker, was put on administrative leave after he was indicted as part of a cocaine drug ring bust in New York. Crumpacker, Chipotle's chief creative and development officer, is reportedly one of the eighteen alleged buyers of cocaine indicted in the drug ring.
comments powered by Disqus
Follow RTT